Pay in 4 interest-free payments of $6.40 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Turn your shot into a clear plan Every part of your week, explained not guessed
The bluebird bio/CRISPR Therapeutics/Vertex CTX001 (now Casgevy) collaboration is a case study: Vertex paid $900 million to acquire CRISPR Therapeutics, taking on both the clinical and IP exposure simultaneously
EMA Decision P/0336/2024 Paediatric Investigation Plan / Waiver for Retatrutide
Oral, intravenous, inhaled, and topical routes each carry distinct side effect risks and bioavailability considerations
For easy snack options, see no appetite snacks for GLP-1 users
US$ 21.57
US$ 29.34
US$ 21.21
US$ 24.35
US$ 20.73
US$ 20.89
